rs11595500 - LINC02645 - PFKP-DT
Magnitude 2.2 · 1 study on file
Reported associations
-
Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy - Unknown journal (n.d.) · Unknown authors · PubMed 26015512
ABSTRACT: Purpose Paclitaxel is used worldwide in the treatment of breast, lung, ovarian and other cancers. Sensory peripheral neuropathy is an associated adverse effect that cannot be predicted, prevented or mitigated. To better understand the contribution of germline genetic variation to paclitaxel-induced peripheral neuropathy, we undertook an integrative approach that combines genome-wide association study (GWAS) data generated from HapMap lymphoblastoid cell lines (LCLs) and Asian patients. Methods GWAS was performed with paclitaxel-induced cytotoxicity generated in 363 LCLs and with paclitaxel-induced neuropathy from 145 Asian patients. A gene-based approach was used to identify overlapping genes and compare to a European clinical cohort of paclitaxel-induced neuropathy. Neurons deri
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
Paclitaxel sensitivity and dosing if chemotherapy prescribed Moderate
rs11595500 genotype predicts paclitaxel-induced cellular cytotoxicity; reference allele carriers show increased sensitivity in pharmacogenomics studies.
If prescribed paclitaxel-based chemotherapy, discuss this variant with your oncology team regarding dosing and neuropathy monitoring